© 2019 Helomics Corp. All rights reserved.

  • White Twitter Icon
  • Facebook - White Circle
  • White LinkedIn Icon

Helomics® Corporation and MDNA Life Sciences, Inc. Announce an Agreement to Commence a Multi-Faceted Strategic Collaboration

January 12, 2017

Companies intend to collaborate regarding sales and marketing, clinical lab testing, and research and development

 

PITTSBURGH AND WEST PALM BEACH– January 12, 2017 - Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, and MDNA Life Sciences, Inc. (MDNA), the molecular diagnostics company pioneering the development of liquid biopsy tests based on the mitochondrial genome, today announced the beginning of a broad strategic relationship.

 

As part of this collaboration, Helomics will promote MDNA’s Prostate Core Mitomic Test™ and its liquid biopsy Prostate Mitomic Test™ in selected U.S. markets and will offer these proprietary tests in its CLIA-approved clinical laboratory.  Additionally, the companies will work together to develop, validate, and commercialize other liquid biopsy-based diagnostic tests utilizing MDNA’s proprietary Mitomic Technology™ platform, which exploits the unique biological characteristics of mitochondrial DNA.  MDNA also intends to grant Helomics a license to offer diagnostic tests, based on MDNA’s proprietary mitochondrial DNA technology, to Helomics’ clients in the pharmaceutical, diagnostic, and biotechnology industries as part of its Contract Research Services offering.

 

Gerald J. Vardzel Jr., President and CEO of Helomics said, “We are very excited about this strategic collaboration with MDNA.  We anticipate that, by leveraging the core expertise of both companies, many new diagnostic tests will be developed and commercialized that will lead to a better understanding of the uniqueness of a patient’s cancer.”  Donald L. Very, Jr., Vice President of Research and Commercial Development at Helomics added, “MDNA is the leading developer of mitochondrial DNA-based diagnostic tests.  Their Mitomic Technology™ platform has the potential to discover novel biomarkers of disease onset, progression, or regression. This platform will be a significant addition to our research service offerings to our partner-clients in the pharmaceutical and diagnostics industries.”   

 

Chris Mitton, President and CEO of MDNA stated, “Helomics’ truly integrated approach to Contract Research Services, which connects key academic centers and leading pharmaceutical companies with innovative diagnostic platforms, creates a unique opportunity for us to expand access to our proprietary Mitomic Technology™ for rapid biomarker discovery across multiple oncology categories.  This strategic relationship with Helomics will enable us to accelerate product development, clinical validation, and the commercialization of our deep pipeline of novel, best-in-class liquid biopsy tests.”

 

 

 

About Helomics® Corporation

Helomics® is an integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace.  Helomics offers advanced clinical laboratory diagnostic tests as well as scientific and non-scientific product enhancement services to provide a customized solution to our client’s specific product development needs.

Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories.  For more information please visit: www.helomics.com.

 

About MDNA Life Sciences

MDNA Life Sciences, Inc. is leading the development of molecular diagnostic tests using its proprietary Mitomic Technology™ platform that exploits the unique biological characteristics of mitochondrial DNA. This innovative platform is a highly attractive and effective system for biomarker discovery, early disease detection, monitoring, risk assessment and therapeutic targeting. It has led to the discovery of numerous novel and proprietary biomarkers for a multitude of cancers and other diseases. The Company is applying its expertise in mitochondrial genomics to develop an extensive and proprietary portfolio of blood-based molecular tests for conditions that are currently dependent on poor or absent screening tests or invasive procedures for detection. For more information visit www.mdnalifesciences.com

 

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:  This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.  

 

For more information regarding Helomics Corporation, please contact:

Michelle Murgia, Marketing Communications and Design, Helomics Corporation

mmurgia@helomics.com

412-432-1363

 

For more information regarding MDNA Life Sciences, Inc., please contact:

Christopher Mitton, President and CEO, MDNA Life Sciences, Inc.
c.mitton@mdnalifesciences.com

844-321-6362

 

Sources: Helomics® Corporation and MDNA Life Sciences, Inc.

Share on Facebook
Share on Twitter
Please reload

Featured Posts

Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis

September 10, 2019

1/10
Please reload

Recent Posts
Please reload

Archive